A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.

Inclusion Criteria:

- Pathologically confirmed adenocarcinoma of the breast.

- Stage IV disease

- Measurable disease

- Patients must not be a candidate for Herceptin therapy

- At least 4 weeks since radiotherapy, with full recovery. The measurable disease must
be completely outside the radiation portal or there must be pathologic proof of
progressive disease within the radiation portal.

- At least 4 weeks since major surgery, with full recovery.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

- Female >18 years of age.

- Patient has the following blood counts at Baseline:

Absolute neutrophil count ≥ 1.5 x 10^9cells/L; platelets ≥ 100 x 10^9 cells/L; hemoglobin
≥ 9 g/dL.

- Patient has the following blood chemistry levels at Baseline: Aspartate
transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) ≤ 2.5x upper limit
of normal range (ULN); total bilirubin ≤ ULN; creatinine ≤ 1.5 mg/dL.

- If female of childbearing potential, pregnancy test is negative within 72 hours of
first dose of study drug.

- If fertile, the patient agrees to use an effective method to avoid pregnancy for the
duration of the study.

- Informed consent has been obtained.

Exclusion Criteria:

- Prior neo-adjuvant or adjuvant chemotherapy is allowed, and patients must have
recovered from the acute toxicity of such therapies. No prior therapy for metastatic
disease is allowed. If a taxane was part of the adjuvant regimen, at least 12 months
should have passed from completion of taxane regimen to relapse. If a
non-taxane-based adjuvant therapy was administered, at least 6 months should have
passed from completion to relapse.

- Concurrent immunotherapy or hormonal therapy.

- Parenchymal brain metastases, including leptomeningeal involvement.

- Inadequately controlled hypertension (defined as blood pressure of > 150/100
mmHg) or New York Heart Association (NYHA) Grade 2 or greater congestive heart
failure.

- Any prior history of hypertensive crisis or hypertensive encephalopathy.

- History of myocardial infarction or unstable angina within 6 months prior to study
enrollment.

- History of stroke or transient ischemic attack within 6 months prior to study
enrollment.

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection).

- Symptomatic peripheral vascular disease.

- Evidence of bleeding diathesis or coagulopathy.

- History of abdominal fistula, gastrointestinal perforation, or intra- abdominal
abscess within 6 months prior to study enrollment.

- Proteinuria at screening as demonstrated by either: - Urine protein:creatinine (UPC)
ratio > 1.0 at screening OR - Urine dipstick for proteinuria ≥ 2+ (patients
discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should
undergo a 24-hour urine collection and must demonstrate ≤ 1g of protein in 24 hours
to be eligible).

- Known hypersensitivity to any component of bevacizumab.

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to first dose.

- Major surgical procedure, open biopsy, or significant traumatic injury within 28
days prior to first dose, anticipation of need for major surgical procedure during
the course of the study. Serious, non-healing wound, ulcer, or bone fracture. Serious
intercurrent medical or psychiatric illness, including serious active infection.

- History of other malignancy within the last 5 years which could affect the diagnosis
or assessment of breast cancer.

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study.

- Pregnant or nursing women.

- Sensory neuropathy of > Grade 1 at baseline.